



Population of invasive group A streptococci isolates from a German tertiary care center is dominated by the hypertoxigenic virulent M1_{UK} genotype

Manuel Wolters¹ · Benjamin Berinson¹ · Nicole Degel-Brossmann¹ · Armin Hoffmann¹ · Rico Bluszis¹ · Martin Aepfelbacher¹ · Holger Rohde¹ · Martin Christner¹

Received: 2 November 2023 / Accepted: 4 November 2023 / Published online: 8 December 2023

© The Author(s) 2023

Abstract

Purpose Hypertoxigenic *Streptococcus pyogenes emm1* lineage M1_{UK} has recently been associated with upsurges of invasive infections and scarlet fever in several countries, but whole-genome sequencing surveillance data of lineages circulating in Germany is lacking. In this study, we investigated recent iGAS isolates from our laboratory at a German tertiary care center for the presence of the M1_{UK} lineage.

Methods Whole-genome sequencing was employed to characterize a collection of 47 consecutive non-copy isolates recovered from blood cultures (21) and tissue samples (26) in our laboratory between October 2022 and April 2023.

Results M protein gene (*emm*) typing distinguished 14 different *emm* types, with *emm1* (17) being the dominant type. Single-nucleotide polymorphism (SNP) analysis confirmed the presence of all 27 SNPs characteristic for the M1_{UK} lineage in 14 of 17 *emm1* isolates.

Conclusion This study has shown for the first time that M1_{UK} is present in Germany and might constitute a driving force in the observed surge of GAS infections. This observation mirrors developments in the UK and other countries and underscores the importance of WGS surveillance to understand the epidemiology of GAS.

Keywords *Streptococcus pyogenes* · Epidemiology · *Emm* type · M1_{UK}

Introduction

Streptococcus pyogenes, also referred to as Group A *Streptococcus* (GAS), is an important human pathogen that causes non-invasive infections such as scarlet fever, pharyngitis and impetigo, and also life-threatening invasive infections (iGAS) such as necrotising fasciitis, pneumonia, meningitis and puerperal sepsis [1]. In 2022 and 2023, several European countries (including Denmark, Ireland, France, the Netherlands, Sweden, Spain, and the UK) have reported a marked increase in scarlet fever and iGAS [2–6]. The observed increase followed a period of low incidence during the COVID-19 pandemic, but has now exceeded pre-pandemic levels [5, 6]. This

phenomenon is likely attributable to reduced exposure at the population level and an associated so-called immunity gap [7], which may have led to widespread dissemination in the population after the lifting of COVID-19-related restrictions. In addition, the current high activity of viral respiratory infections might have contributed to an increase in iGAS cases with a respiratory focus [6, 8]. On the other hand, an increase of scarlet fever and iGAS had been observed in the UK some years before the pandemic and was associated with the emergence and spread of a new lineage of *S. pyogenes* designated M1_{UK} [9]. The M1_{UK} lineage is a variant of the highly successful, contemporary epidemic M1_{global} strain [10]. M1_{UK} is differentiated from M1_{global} by 27 chromosomal single nucleotide polymorphisms (SNPs) and exhibits enhanced expression of the superantigenic scarlet fever toxin SpeA (streptococcal pyrogenic exotoxin A) in vitro [9, 11]. The M1_{UK} lineage has subsequently been identified in several other countries (Australia, Belgium, Canada, Netherlands, Portugal, Scotland, USA) [3, 8, 11–15], where in some cases (Australia, Belgium, Netherlands, Portugal) it has also expanded and displaced

✉ Holger Rohde
rohde@uke.de

¹ Institut für Medizinische Mikrobiologie, Virologie und Hygiene, Universitätsklinikum Hamburg-Eppendorf (UKE), Martinistrasse 52, 20246 Hamburg, Germany

the M1_{global} lineage [11, 12, 16, 17]. Recently, the emergence and spread of two more new clones designated M1_{DK} (*emm1*) and M4_{NL22} (*emm4*) were reported in Denmark and the Netherlands, respectively [4, 18]. In Germany, the Robert Koch Institute (RKI) also reported a strong increase in iGAS infections for the fourth quarter of 2022 [19]. RKI surveillance data also show a marked increase in the number of reported scarlet fever cases from two federated German states with mandatory scarlet fever reporting (<https://survstat.rki.de/>; accessed 2023/08/25). This trend was reflected in the number of GAS/iGAS isolates recovered from clinical samples at our laboratory (Fig. 1). Currently, whole-genome surveillance data of circulating *S. pyogenes* strains from Germany is not yet available. To explore the GAS population and to elucidate whether any of the epidemic clones recently described in neighbouring countries might have contributed to the reported increase in iGAS infections, we analysed a collection of 47 *S. pyogenes* isolates recovered from blood and tissue samples from October 2022 to April 2023 by whole-genome sequencing.

Results and discussion

The *S. pyogenes* M1_{UK} lineage has emerged and rapidly spread in several countries worldwide. Owing to the lack of nationwide whole-genome surveillance data for *S. pyogenes*, information on the presence of the M1_{UK} lineage in Germany is not yet available. This prompted us to characterize the population structure of contemporary *S. pyogenes* isolated during routine diagnostic workup of blood cultures and tissue samples at the microbiology laboratory of the

University Medical Center Hamburg-Eppendorf, a 1600-bed tertiary care center. Between October 2022 and April 2023, a total of 53 non-copy *S. pyogenes* isolates were recovered from eligible specimens. Of those, 47 (21 blood culture isolates and 26 isolates from tissue specimens) were available for whole-genome sequencing and subsequent delineation of the recently described new M1_{UK}, M1_{DK} and M4_{NL22} lineages (supplemental file 1). M protein gene (*emm*) typing distinguished 14 different *emm* types, with *emm1* [17] being the dominant type, followed by *emm89* [7] (Table 1). Single-nucleotide polymorphism (SNP) analysis confirmed the presence of all 27 SNPs characteristic for the M1_{UK} lineage

Table 1 Distribution of *emm* types

<i>emm</i> type	Number [n]
1	17 (14 M1 _{UK})
12	6
89	6
27	3
49	3
53	2
66	2
87	2
4	1
11	1
77	1
102	1
106	1
218	1
Total	47




Fig. 1 Monthly cases of GAS infections identified by our laboratory between 7/2017 and 6/2023. Total number of cases and cases of invasive infections (iGAS) are represented by light and dark grey bars,

respectively. Numbers above the light grey bars indicate the number of all GAS detections in the respective period, and numbers above the dark grey bars indicate the number of iGAS

[9] in 14 of 17 *emm1* isolates. The remaining three *emm1* isolates lacked any of the M1_{UK}-defining SNPs. SNP-based phylogenetic analysis grouped our M1_{UK} isolates together with representative M1_{UK} isolates recovered from iGAS in the UK, Australia, Canada and the USA and separated them from the M1_{global} and M1_{inter} lineages. M1_{inter} lineages carry subsets of the SNPs that define M1_{UK}, but failed to spread as successful as M1_{UK} [9, 11] (Fig. 2). Analysis of virulence and resistance gene content of our 14 M1_{UK} isolates revealed no striking differences as compared to other M1_{UK} or local M1_{global} strains (supplemental file 1) [9]. The *emm1* clone M1_{DK}, reported to be highly prevalent in Denmark [4], was not found, and only one isolate of *emm4*, a prevalent genotype in invasive infections in the Netherlands [18], was identified in our collection.

In conclusion, this study has shown for the first time that M1_{UK} is present in Germany and might constitute a driving force in the observed surge of GAS infections. We concede that our study is only a snapshot of a regional *S. pyogenes* population, which may not be representative of the German *S. pyogenes* population. In addition, due to the lack of patient travel information, acquisition of M1_{UK} GAS outside of Germany cannot be excluded in all cases. Our study population also did not encompass commensal isolates or isolates from cases of uncomplicated pharyngitis and might thus not reflect the overall composition of our local *S. pyogenes* population. Nevertheless, our preliminary data underscore the need for further studies of larger strain collections to reconstruct the spread of M1_{UK} in Germany and elucidate its role in the current surge of GAS infections [19].




Fig. 2 Maximum likelihood phylogenetic tree from core SNPs (excluding prophage regions). Isolates are labelled with accession numbers; isolates sequenced for the present study are shown in orange boldface print. M1 lineage is indicated by shading of the inner

doughnut plot. Region of strain origin is indicated by coloured rectangles. Nodes with bootstrap support values lower than 70% have been collapsed, and bootstrap support values between 70 and 99% are marked with circles

Methods

S. pyogenes study isolates (n=47) were thawed from a -80 °C cryo-collection of contemporary isolates and underwent WGS. In brief, DNA was extracted using QiaSymphony mericon extraction kits (Qiagen) on a QiaSymphony SP instrument according to the manufacturer's instructions. Libraries for paired end sequencing were prepared using the NEB NextUltra II DNA library Prep Kit for Illumina (NEB) and sequenced with 2 × 150 cycles on an Illumina MiSeq instrument. Reads or nucleotide sequences from additional isolates were obtained from the National Center for Biotechnology Information (NCBI) sequence read archive, the NCBI reference sequence database and the European Nucleotide Archive (ENA). Reads were assembled with shovill 1.1 employing spades 3.15.5 [20], annotated with bakta 1.8.1 [21] and subjected to pan genome analysis with roary 3.13.0 [21]. *Emm* types were assigned from bakta assemblies using the Centers for Disease Control *Streptococcus* Laboratory GAS bioinformatic pipeline (https://github.com/BenJamesMetcalf/GAS_Scripts_Reference). Resistance genes were detected using AMRFinderPlus 3.11.14 with the NCBI reference gene database version 2023-08-08.2 [22]. Known virulence markers were identified with abricate 1.0.1 (<https://github.com/tseemann/abricate>) and the virulence factor database version 2022-08-26 [23]. Additional allelic profiling was performed with chewBBACA 3.3.0 [24] and a *S. pyogenes* wgMLST schema from Chewie-NS [25]. Core SNPs were identified with snippy 4.6.0 (<https://github.com/tseemann/snippy>) using *S. pyogenes* MGAS5005 (GenBank accession NC_007297.2) as a reference. Maximum likelihood phylogenies from concatenated core SNPs were constructed using gubbins 3.3.0 [26] with IQTree [27] and visualized with TreeViewer 2.1.0 (<https://github.com/arklumpus/TreeViewer/tree/v2.1.0>).

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s15010-023-02137-1>.

Acknowledgements The authors would like to thank the technical staff of the Institute of Medical Microbiology, Virology and Hygiene for their excellent support.

Author contributions M.W. Designed the study, analyzed data, wrote the manuscript. B.B. Performed experiments, analyzed data, edited the manuscript. N.D-B. Performed experiments, analyzed data, edited the manuscript. A.H. Performed experiments, prepared figure 1, edited the manuscript. R.B. Performed experiments, edited the manuscript. M.A. Provided resources, edited the manuscript. M.C. Performed experiments, analyzed data, prepared figures 1 and 2, wrote the manuscript. H.R. Designed the study, analyzed data, wrote the manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL. No funds, grants or other support was received.

Data availability Whole genome sequences generated for this study are available in the European Nucleotide Archive at <https://www.ebi.ac.uk/ena/browser/home> and can be accessed with the project number PRJEB64404. Isolate metadata are available in the online supplementary material.

Declarations

Conflict of interest The authors have no competing interests to declare that are relevant to the content of this article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Walker MJ, Barnett TC, McArthur JD, Cole JN, Gillen CM, Henningham A, Sriprakash KS, Sanderson-Smith ML, Nizet V. Disease manifestations and pathogenic mechanisms of group A streptococcus. *Clin Microbiol Rev.* 2014;27:264–301.
- WHO. Increase in invasive group A streptococcal infections among children in Europe, including fatalities. WHO; 2022.
- van der Putten BCL, Vlaminckx BJM, de Gier B, Freudenburg-de Graaf W, van Sorge NM. Group A streptococcal meningitis with the M1UK variant in the Netherlands. *JAMA.* 2023;329:1791–2.
- Johannesen TB, Munkstrup C, Edslev SM, Baig S, Nielsen S, Funk T, Kristensen DK, Jacobsen LH, Ravn SF, Bindslev N, Gubbels S, Voldstedlund M, Jokelainen P, Hallstrom S, Rasmussen A, Kristinsson KG, Fuglsang-Damgaard D, Dessau RB, Olsen AB, Jensen CS, Skovby A, Ellermann-Eriksen S, Jensen TG, Dzajic E, Ostergaard C, Lomborg Andersen S, Hoffmann S, Andersen PH, Stegger M. Increase in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent *Streptococcus pyogenes* M1 clone, Denmark, 2023. *Euro Surveill.* 2023. <https://doi.org/10.2807/1560-7917.ES.2023.28.26.2300291>.
- Cobo-Vazquez E, Aguilera-Alonso D, Carrasco-Colom J, Calvo C, Saavedra-Lozano J, Ped GASNWG. Increasing incidence and severity of invasive group A streptococcal disease in Spanish children in 2019–2022. *Lancet Reg Health Europe.* 2023;27:100597.
- Lassoued Y, Assad Z, Ouldali N, Caseris M, Mariani P, Birgy A, Bonacorsi S, Bidet P, Faye A. Unexpected increase in invasive group A streptococcal infections in children after respiratory viruses outbreak in france: a 15-year time-series analysis. *Open Forum Infect Dis.* 2023;10:188.

7. Messacar K, Baker RE, Park SW, Nguyen-Tran H, Cataldi JR, Grenfell B. Preparing for uncertainty: endemic paediatric viral illnesses after COVID-19 pandemic disruption. *Lancet*. 2022;400:1663–5.
8. Davies PJB, Russell CD, Morgan AR, Taori SK, Lindsay D, Ure R, Brown D, Smith A. Increase of severe pulmonary infections in adults caused by M1(UK) *Streptococcus pyogenes*, Central Scotland UK. *Emerg Infect Dis*. 2023;29:1638.
9. Lynskey NN, Jauneikaite E, Li HK, Zhi X, Turner CE, Mosavie M, Pearson M, Asai M, Lobkowicz L, Chow JY, Parkhill J, Lamagni T, Chalker VJ, Sriskandan S. Emergence of dominant toxigenic MIT1 *Streptococcus pyogenes* clone during increased scarlet fever activity in England: a population-based molecular epidemiological study. *Lancet Infect Dis*. 2019;19:1209–18.
10. Nasser W, Beres SB, Olsen RJ, Dean MA, Rice KA, Long SW, Kristinsson KG, Gottfredsson M, Vuopio J, Raisanen K, Caugant DA, Steinbakk M, Low DE, McGeer A, Darenberg J, Henriques-Normark B, Van Beneden CA, Hoffmann S, Musser JM. Evolutionary pathway to increased virulence and epidemic group A *Streptococcus* disease derived from 3,615 genome sequences. *Proc Natl Acad Sci USA*. 2014;111:E1768–1776.
11. Davies MR, Keller N, Brouwer S, Jespersen MG, Cork AJ, Hayes AJ, Pitt ME, De Oliveira DMP, Harbison-Price N, Bertolla OM, Mediati DG, Curren BF, Taiaroa G, Lacey JA, Smith HV, Fang NX, Coin LJM, Stevens K, Tong SYC, Sanderson-Smith M, Tree JJ, Irwin AD, Grimwood K, Howden BP, Jennison AV, Walker MJ. Detection of *Streptococcus pyogenes* M1(UK) in Australia and characterization of the mutation driving enhanced expression of superantigen SpeA. *Nat Commun*. 2023;14:1051.
12. Rumke LW, de Gier B, Vestjens SMT, van der Ende A, van Sorge NM, Vlamincxx BJM, Witteveen S, van Santen M, Schouls LM, Kuijper EJ. Dominance of M1(UK) clade among Dutch M1 *Streptococcus pyogenes*. *Lancet Infect Dis*. 2020;20:539–40.
13. Li Y, Nanduri SA, Van Beneden CA, Beall BW. M1(UK) lineage in invasive group A streptococcus isolates from the USA. *Lancet Infect Dis*. 2020;20:538–9.
14. Demczuk W, Martin I, Domingo FR, MacDonald D, Mulvey MR. Identification of *Streptococcus pyogenes* M1(UK) clone in Canada. *Lancet Infect Dis*. 2019;19:1284–5.
15. Li Y, Rivers J, Mathis S, Li Z, Chochua S, Metcalf BJ, Beall B, Onukwube J, Gregory CJ, McGee L. Expansion of invasive group A streptococcus M1(UK) lineage in active bacterial core surveillance, United States, 2019–2021. *Emerg Infect Dis*. 2023;29:2116–20.
16. Rodriguez-Ruiz JP, Lin Q, Lammens C, Smeesters PR, van Kleef-van Koeveringe S, Matheussen V, Malhotra-Kumar S. Increase in bloodstream infections caused by emm1 group A streptococcus correlates with emergence of toxigenic M1(UK), Belgium, May 2022 to August 2023. *Euro Surveill*. 2023;28:2300422.
17. Gouveia C, Bajanca-Lavado MP, Mamede R, Araujo Carvalho A, Rodrigues F, Melo-Cristino J, Ramirez M, Friaes A, Portuguese Study Group of Pediatric Invasive Streptococcal, D., and Portuguese Study Group of Paediatric Invasive Streptococcal, D. Sustained increase of paediatric invasive *Streptococcus pyogenes* infections dominated by M1(UK) and diverse emm12 isolates, Portugal, September 2022 to May 2023. *Euro Surveill*. 2023;28:2300427.
18. van der Putten BCL, Bril-Keijzers WCM, Rumke LW, Vestjens SMT, Koster LAM, Willemssen M, van Houten MA, Rots NY, Vlamincx BJM, de Gier B, van Sorge NM. Novel emm4 lineage associated with an upsurge in invasive group A streptococcal disease in the Netherlands, 2022. *Microb Genom*. 2023. <https://doi.org/10.1099/mgen.0.001026>.
19. RKI. Epidemiologisches Bulletin. 2023.
20. Prjibelski A, Antipov D, Meleshko D, Lapidus A, Korobeynikov A. Using SPAdes De Novo assembler. *Curr Protoc Bioinform*. 2020;70: e102.
21. Schwengers O, Jelonek L, Dieckmann MA, Beyvers S, Blom J, Goesmann A. Bakta: rapid and standardized annotation of bacterial genomes via alignment-free sequence identification. *Microb Genom*. 2021. <https://doi.org/10.1099/mgen.0.000685>.
22. Feldgarden M, Brover V, Gonzalez-Escalona N, Frye JG, Haendiges J, Haft DH, Hoffmann M, Pettengill JB, Prasad AB, Tillman GE, Tyson GH, Klimke W. AMRFinderPlus and the reference gene catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. *Sci Rep*. 2021;11:12728.
23. Chen L, Zheng D, Liu B, Yang J, Jin Q. VFDB 2016: hierarchical and refined dataset for big data analysis—10 years on. *Nucleic Acids Res*. 2016;44:D694–697.
24. Silva M, Machado MP, Silva DN, Rossi M, Moran-Gilad J, Santos S, Ramirez M, Carrico JA. chewBBACA: a complete suite for gene-by-gene schema creation and strain identification. *Microb Genom*. 2018. <https://doi.org/10.1099/mgen.0.000166>.
25. Friaes A, Mamede R, Ferreira M, Melo-Cristino J, Ramirez M. Annotated whole-genome multilocus sequence typing schema for scalable high-resolution typing of *Streptococcus pyogenes*. *J Clin Microbiol*. 2022;60: e0031522.
26. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, Parkhill J, Harris SR. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. *Nucleic Acids Res*. 2015;43: e15.
27. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, Lanfear R. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. *Mol Biol Evol*. 2020;37:1530–4.